Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.
Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). Lokhorst HM, et al. Among authors: minnema mc. Blood. 2010 Feb 11;115(6):1113-20. doi: 10.1182/blood-2009-05-222539. Epub 2009 Oct 30. Blood. 2010. PMID: 19880501 Free article. Clinical Trial.
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, Minnema MC, van Oers MH, Raymakers RA, Schaafsma MR, Vellenga E, Wijermans PW, Wittebol S, Sonneveld P, Zweegman S. Kneppers E, et al. Among authors: minnema mc. Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):138-43. doi: 10.3816/CLML.2010.n.020. Clin Lymphoma Myeloma Leuk. 2010. PMID: 20371448
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB, Bruijnen CP, Emmelot M, Sonneveld P, Lokhorst HM, Mutis T, Minnema MC. Kneppers E, et al. Among authors: minnema mc. Blood. 2011 Sep 1;118(9):2413-9. doi: 10.1182/blood-2011-04-348292. Epub 2011 Jun 20. Blood. 2011. PMID: 21690556 Free article. Clinical Trial.
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Lokhorst HM, et al. Among authors: minnema mc. Blood. 2012 Jun 28;119(26):6219-25; quiz 6399. doi: 10.1182/blood-2011-11-393801. Epub 2012 Mar 22. Blood. 2012. PMID: 22442350 Free article. Clinical Trial.
Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review.
Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters-van den Bos IC, Heggelman BG, Nievelstein RJ, Otten RH, van Lammeren-Venema D, Zijlstra JM, Arens AI, de Rooy JW, Hoekstra OS, Raymakers R, Sonneveld P, Ostelo RW, Zweegman S. Regelink JC, et al. Among authors: minnema mc. Br J Haematol. 2013 Jul;162(1):50-61. doi: 10.1111/bjh.12346. Epub 2013 Apr 25. Br J Haematol. 2013. PMID: 23617231 Free article.
Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Lokhorst HM, et al. Among authors: minnema mc. Haematologica. 2015 Dec;100(12):e508-10. doi: 10.3324/haematol.2015.128728. Epub 2015 Sep 4. Haematologica. 2015. PMID: 26341740 Free PMC article. Clinical Trial. No abstract available.
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW. Nijhof IS, et al. Among authors: minnema mc. Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15. Blood. 2016. PMID: 27307294 Free article. Clinical Trial.
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG. Plesner T, et al. Among authors: minnema mc. Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16. Blood. 2016. PMID: 27531679 Free PMC article. Clinical Trial.
184 results